Aspirin/Dipyridamole

阿司匹林/双嘧达莫

Report date: 2026/03/23 20:03:44

Base Information

Drug NameAspirin/Dipyridamole
Drug Alias Name阿司匹林双嘧达莫Dipyridamole/AspirinAspirin and Dipyridamole双嘧达莫/阿司匹林乙酰水杨酸/双嘧达莫 +[9] 
ClassificationSmall molecules
Mechanisms of ActionCyclooxygenases inhibitors3',5'-cyclic phosphodiesterase inhibitors
TargetsCyclooxygenases3',5'-cyclic phosphodiesterase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)StrokeCerebral Infarction
Global Approved IndicationsStrokeCerebral Infarction
Approved Indications in ChinaCerebral Infarction
Original Approved Country/TerritoryMainland China
Original Approved Date1994/01/01
Country/TerritoryUnited StatesTaiwanFrance +[5] 
CombinationsYes AspirinDipyridamole
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgRutgers UniversityDezhou Bocheng Pharmaceutical Co Ltd
Inactive CompaniesBoehringer Ingelheim International Gmbh
Active IndicationsCoronavirus Disease 2019 (COVID-19)StrokeCerebral Infarction
Inactive IndicationsN/A

Other Information

ATC CodeA01AD05B01AC06N02BA01
Related LinksWikipedia